In terms of safety, what is a major concern when administering promethazine to young children?

The primary concern when administering promethazine to young children is the risk of fatal respiratory depression. Promethazine is an antihistamine with sedative properties, and in young children, particularly those under the age of two, it has been associated with severe respiratory complications, including respiratory depression that can lead to fatalities. The safety profile of promethazine indicates that the central nervous system effects can be more pronounced in this age group, increasing the risk of significant respiratory side effects.

While drowsiness and agitation can occur, they typically do not present the same level of critical risk as respiratory depression. Similarly, constipation may be a side effect but is generally not life-threatening. Therefore, the potential for respiratory depression is a major safety concern that necessitates careful consideration and monitoring when administering this medication to young children.